스마트 인슐린 투여 시스템 시장 : 시장 분석 및 예측 - 유형별, 제품 유형별, 기술별, 구성요소별, 용도별, 디바이스별, 최종 사용자별, 기능별, 솔루션별, 투여 모드별(-2035년)

The global Smart Insulin Delivery Systems Market is projected to grow from $9.9 billion in 2025 to $19.4 billion by 2035, at a compound annual growth rate (CAGR) of 7.0%. The Smart Insulin Delivery Systems Market is driven by demand for automated glucose management, personalized insulin dosing, and connected diabetes-care technologies. In June 2026, the U.S. FDA cleared the Omnipod 6 Automated Insulin Delivery System, combining an automated insulin-dosing algorithm, ACE pump, and compatible continuous glucose monitor. Smart systems increasingly integrate CGMs, insulin pumps, dosing algorithms, smartphone connectivity, and predictive glucose control to automatically adjust insulin delivery. These technologies are supporting more personalized diabetes management while reducing manual dosing requirements and enabling continuous, connected monitoring.

The Type segment of the Smart Insulin Delivery Systems Market includes Continuous Glucose Monitoring Systems, Smart Insulin Pens, Insulin Pumps, Closed-loop Systems, and Others. Insulin Pumps dominated the market in 2025 due to their ability to provide precise, continuous insulin delivery and support personalized diabetes management. Increasing integration with continuous glucose monitoring and automated dosing technologies is further supporting adoption. Closed-loop Systems are expected to be the fastest-growing segment during the forecast period, driven by increasing demand for automated insulin delivery, real-time glucose monitoring, and improved glycemic management. Advancements in artificial intelligence, machine learning, connectivity, and sensor technologies are expected to further enhance the performance and adoption of closed-loop systems.

The End User segment of the Smart Insulin Delivery Systems Market includes Hospitals, Home Care Settings, Specialty Clinics, Diabetes Care Centers, and Others. Home Care Settings dominated the market in 2025 due to the growing preference for convenient, continuous, and technology-enabled diabetes management outside clinical environments. Connected insulin delivery devices enable patients and caregivers to monitor treatment and manage insulin administration remotely. Diabetes Care Centers are expected to be the fastest-growing segment during the forecast period, supported by increasing diabetes prevalence, specialized disease-management programs, and greater adoption of integrated glucose monitoring and insulin delivery technologies. Growing emphasis on personalized diabetes care and remote patient monitoring is expected to further increase adoption in specialized diabetes care settings.

Geographical Overview

North America was the leading region in the Smart Insulin Delivery Systems Market in 2025, supported by advanced diabetes-care infrastructure, high adoption of connected insulin delivery technologies, strong healthcare expenditure, and established reimbursement systems. The region benefits from widespread use of smart insulin pens, insulin pumps, continuous glucose monitoring, and automated insulin delivery systems. The United States represents the major contributor, supported by a large population requiring insulin therapy, sophisticated endocrinology and diabetes-care networks, and strong presence of medical-device manufacturers. Increasing integration of insulin delivery systems with digital health platforms, remote monitoring, and personalized treatment technologies further supported regional demand.

Asia-Pacific is expected to be the fastest-growing region in the Smart Insulin Delivery Systems Market during the forecast period, driven by the rising prevalence of diabetes, expanding healthcare infrastructure, increasing healthcare expenditure, and growing adoption of connected and automated insulin delivery technologies. China, India, Japan, South Korea, and Australia are expected to contribute significantly to regional expansion as access to advanced diabetes-management solutions improves. Growing government initiatives, expanding insurance coverage, increasing digital-health adoption, and investments in smart insulin pens, pumps, and automated delivery systems are expected to support market development. The growing demand for convenient, personalized, and minimally invasive diabetes-management solutions will further encourage adoption across the region.

Key Trends and Drivers

Shift Toward Fully Automated, Adaptive Insulin Delivery:

The Smart Insulin Delivery Systems Market is trending toward increasingly autonomous systems that integrate continuous glucose monitoring (CGM), insulin pumps, predictive algorithms, and adaptive control software to adjust insulin delivery in real time. Next-generation systems are moving beyond conventional hybrid closed-loop operation toward reducing the need for manual meal announcements and other user interventions. AI and machine-learning approaches are being investigated to personalize insulin dosing according to individual glucose patterns, insulin sensitivity, meals, exercise, and daily variability. The American Diabetes Associations 2026 Standards of Care identify automated insulin delivery (AID) as the preferred insulin-delivery method for people with type 1 diabetes, reinforcing the shift toward intelligent, automated therapy.

Growing Demand for Better Glycemic Control and Reduced Hypoglycemia:

A major driver for the Smart Insulin Delivery Systems Market is the need to improve time in glucose range while reducing hyperglycemia and hypoglycemia without requiring constant manual insulin adjustments. Smart delivery systems continuously use CGM data and control algorithms to increase, decrease, or suspend insulin delivery according to changing glucose levels. The 2026 ADA Standards report that AID systems improve time in range, lower A1C, and reduce hypoglycemia compared with conventional insulin-delivery approaches. Evidence is also expanding beyond type 1 diabetes, with a 2026 systematic review finding that AID improved glucose control and reduced hypoglycemia in insulin-treated people with type 2 diabetes.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Component
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Functionality
• 2.8 Key Market Highlights by Device
• 2.9 Key Market Highlights by Solutions
• 2.10 Key Market Highlights by Mode

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Continuous Glucose Monitoring Systems
  • 4.1.2 Smart Insulin Pens
  • 4.1.3 Insulin Pumps
  • 4.1.4 Closed-loop Systems
  • 4.1.5 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Wearable Devices
  • 4.2.2 Implantable Devices
  • 4.2.3 Handheld Devices
  • 4.2.4 Accessories
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Bluetooth
  • 4.3.2 Wi-Fi
  • 4.3.3 Near Field Communication (NFC)
  • 4.3.4 Artificial Intelligence
  • 4.3.5 Machine Learning
  • 4.3.6 Internet of Things (IoT)
  • 4.3.7 Cloud Computing
  • 4.3.8 Others
• 4.4 Market Size & Forecast by Component (2020-2035)
  • 4.4.1 Sensors
  • 4.4.2 Transmitters
  • 4.4.3 Receivers
  • 4.4.4 Software
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Type 1 Diabetes
  • 4.5.2 Type 2 Diabetes
  • 4.5.3 Gestational Diabetes
  • 4.5.4 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Home Care Settings
  • 4.6.3 Specialty Clinics
  • 4.6.4 Diabetes Care Centers
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Functionality (2020-2035)
  • 4.7.1 Real-time Monitoring
  • 4.7.2 Data Analytics
  • 4.7.3 Automated Insulin Delivery
  • 4.7.4 Remote Monitoring
  • 4.7.5 Others
• 4.8 Market Size & Forecast by Device (2020-2035)
  • 4.8.1 Patch Pumps
  • 4.8.2 Tethered Pumps
  • 4.8.3 Smart Insulin Pens
  • 4.8.4 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Integrated Systems
  • 4.9.2 Standalone Systems
  • 4.9.3 Others
• 4.10 Market Size & Forecast by Mode (2020-2035)
  • 4.10.1 Invasive
  • 4.10.2 Non-invasive
  • 4.10.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Component
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Functionality
    • 5.2.1.8 Device
    • 5.2.1.9 Solutions
    • 5.2.1.10 Mode
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Component
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Functionality
    • 5.2.2.8 Device
    • 5.2.2.9 Solutions
    • 5.2.2.10 Mode
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Component
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Functionality
    • 5.2.3.8 Device
    • 5.2.3.9 Solutions
    • 5.2.3.10 Mode
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Component
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Functionality
    • 5.3.1.8 Device
    • 5.3.1.9 Solutions
    • 5.3.1.10 Mode
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Component
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Functionality
    • 5.3.2.8 Device
    • 5.3.2.9 Solutions
    • 5.3.2.10 Mode
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Component
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Functionality
    • 5.3.3.8 Device
    • 5.3.3.9 Solutions
    • 5.3.3.10 Mode
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Component
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Functionality
    • 5.4.1.8 Device
    • 5.4.1.9 Solutions
    • 5.4.1.10 Mode
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Component
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Functionality
    • 5.4.2.8 Device
    • 5.4.2.9 Solutions
    • 5.4.2.10 Mode
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Component
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Functionality
    • 5.4.3.8 Device
    • 5.4.3.9 Solutions
    • 5.4.3.10 Mode
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Component
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Functionality
    • 5.4.4.8 Device
    • 5.4.4.9 Solutions
    • 5.4.4.10 Mode
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Component
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Functionality
    • 5.4.5.8 Device
    • 5.4.5.9 Solutions
    • 5.4.5.10 Mode
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Component
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Functionality
    • 5.4.6.8 Device
    • 5.4.6.9 Solutions
    • 5.4.6.10 Mode
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Component
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Functionality
    • 5.4.7.8 Device
    • 5.4.7.9 Solutions
    • 5.4.7.10 Mode
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Component
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Functionality
    • 5.5.1.8 Device
    • 5.5.1.9 Solutions
    • 5.5.1.10 Mode
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Component
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Functionality
    • 5.5.2.8 Device
    • 5.5.2.9 Solutions
    • 5.5.2.10 Mode
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Component
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Functionality
    • 5.5.3.8 Device
    • 5.5.3.9 Solutions
    • 5.5.3.10 Mode
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Component
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Functionality
    • 5.5.4.8 Device
    • 5.5.4.9 Solutions
    • 5.5.4.10 Mode
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Component
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Functionality
    • 5.5.5.8 Device
    • 5.5.5.9 Solutions
    • 5.5.5.10 Mode
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Component
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Functionality
    • 5.5.6.8 Device
    • 5.5.6.9 Solutions
    • 5.5.6.10 Mode
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Component
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Functionality
    • 5.6.1.8 Device
    • 5.6.1.9 Solutions
    • 5.6.1.10 Mode
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Component
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Functionality
    • 5.6.2.8 Device
    • 5.6.2.9 Solutions
    • 5.6.2.10 Mode
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Component
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Functionality
    • 5.6.3.8 Device
    • 5.6.3.9 Solutions
    • 5.6.3.10 Mode
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Component
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Functionality
    • 5.6.4.8 Device
    • 5.6.4.9 Solutions
    • 5.6.4.10 Mode
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Component
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Functionality
    • 5.6.5.8 Device
    • 5.6.5.9 Solutions
    • 5.6.5.10 Mode

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Medtronic
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Insulet Corporation
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Tandem Diabetes Care
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Dexcom
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Abbott Laboratories
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Roche Diabetes Care
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Ypsomed
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Novo Nordisk
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Sanofi
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Eli Lilly and Company
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Beta Bionics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bigfoot Biomedical
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Glooko
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Diabeloop
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Senseonics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Biocon
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Cellnovo
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Valeritas
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 DreaMed Diabetes
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 SmartDose Technologies,
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us